TY - JOUR
T1 - Glucan particles are a powerful adjuvant for the HBsAg, favoring antiviral immunity
AU - Soares, Edna
AU - Groothuismink, Zwier M.A.
AU - Boonstra, André
AU - Borges, Olga
N1 - Funding Information:
This work was financed by the European Regional Development Fund (ERDF), through the Centro 2020 Regional Operational Programme under project CENTRO-01-0145-FEDER-000008:BrainHealth 2020 and through the COMPETE 2020Operational Programme for Competitiveness and Internationalisation and Portuguese national funds via FCT (Fundaca̧ õ para a Cienciâ e a Tecnologia), I.P., under projecst PROSAFE/0001/2016, POCI-01-0145-FEDER-030331, and the strategic project POCI-01-0145-FEDER-007440 (UID/NEU/04539/2013). E.S. has a PhD fellowship from FCT (DFRH-SFRH/BD/96167/2013). We thank Luisa Cortes and Margarida Caldeira from the Microscopy Imaging Center of Coimbra (MICC-CNC) and Isabel Nunes e Candidâ Mendes from the CNC flow cytometry unit.
Publisher Copyright:
© 2019 American Chemical Society.
PY - 2019/5/6
Y1 - 2019/5/6
N2 - The lack of vaccine adjuvants that are able to induce robust T cell responses fosters the search for more powerful options. Pathogen-like particles are a promising approach. The adjuvant activity of pathogen-like particles is highly influenced by size and surface composition. This study aimed to evaluate the adjuvant potential of two different β-glucan-based particles, blend chitosan/β-glucan particles (ChiGluPs), which are positively charged and have mean size of 1276 nm, and neutral yeast-derived glucan particles (GPs), with a mean size of 3 μm. Additionally, chitosan particles (ChiPs) were used to understand the effect of β-glucan addition (ChiGluPs). Mouse spleen cells responded through the production of either TNF-α or RANTES, following in vitro stimulation with particles containing either β-glucan (ChiGluPs and GPs) or chitosan (ChiGluPs and ChiPs). Human monocytes responded to all particles through TNF-α secretion. Subcutaneous vaccination of mice with the hepatitis B surface antigen (HBsAg) showed increased serum IgG for all particles compared to HBsAg alone (435-, 4500-, or 2500-fold increase for either ChiPs, ChiGluPs, or GPs). Interestingly, only GPs elicited the secretion of HBsAg-specific Th1, Th2, Th9, Th17, Th22, and Treg-related cytokines. This study demonstrates, for the first time, that GPs can have a significant role against the hepatitis B virus by favoring antiviral immunity.
AB - The lack of vaccine adjuvants that are able to induce robust T cell responses fosters the search for more powerful options. Pathogen-like particles are a promising approach. The adjuvant activity of pathogen-like particles is highly influenced by size and surface composition. This study aimed to evaluate the adjuvant potential of two different β-glucan-based particles, blend chitosan/β-glucan particles (ChiGluPs), which are positively charged and have mean size of 1276 nm, and neutral yeast-derived glucan particles (GPs), with a mean size of 3 μm. Additionally, chitosan particles (ChiPs) were used to understand the effect of β-glucan addition (ChiGluPs). Mouse spleen cells responded through the production of either TNF-α or RANTES, following in vitro stimulation with particles containing either β-glucan (ChiGluPs and GPs) or chitosan (ChiGluPs and ChiPs). Human monocytes responded to all particles through TNF-α secretion. Subcutaneous vaccination of mice with the hepatitis B surface antigen (HBsAg) showed increased serum IgG for all particles compared to HBsAg alone (435-, 4500-, or 2500-fold increase for either ChiPs, ChiGluPs, or GPs). Interestingly, only GPs elicited the secretion of HBsAg-specific Th1, Th2, Th9, Th17, Th22, and Treg-related cytokines. This study demonstrates, for the first time, that GPs can have a significant role against the hepatitis B virus by favoring antiviral immunity.
KW - Chitosan
KW - Hepatitis B antigen
KW - Polymeric particles
KW - Vaccine adjuvants
KW - β-glucan
UR - http://www.scopus.com/inward/record.url?scp=85065426498&partnerID=8YFLogxK
U2 - 10.1021/acs.molpharmaceut.8b01322
DO - 10.1021/acs.molpharmaceut.8b01322
M3 - Article
C2 - 30964694
AN - SCOPUS:85065426498
SN - 1543-8384
VL - 16
SP - 1971
EP - 1981
JO - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
IS - 5
ER -
